斯克裏普斯研究所

2023年6月21日

分享這篇文章提供的新聞考夫曼博士加入Oncternal療法,Inc .普林斯頓大學,新澤西州2023年6月21日,Kyowa從麒麟,Inc .的Kyowa麒麟有限公司有限公司(Kyowa麒麟,謝霆鋒:4151),日本的全球專業製藥公司,今天宣布貢納·考夫曼博士已經被命名為研究總監(CRO)。考夫曼博士加入Kyowa麒麟北美(KKNA) Oncternal療法,Inc .,在那裏他擔任首席科學官。在他的新角色,考夫曼博士將負責KKNA位於拉霍亞的研究團隊,CA,以及開放創新部門,尋求外部合作加速藥物發現和新的生物技術的應用。他也擔任兼職助理教授斯克裏普斯研究所的化學和免疫學和微生物科學的部門。貢納·f·考夫曼博士命名研究總監Kyowa麒麟”考夫曼博士的領先的藥物發現研究和臨床前開發將有助於Kyowa麒麟增長我們的未來管道新的藥物靶點和治療候選人有可能解決患者的未滿足的需求”,有利於牌坊博士說,全球研究主管Kyowa麒麟。“我們期待著持續增長與學術和技術合作夥伴的合作來滿足我們的科學和臨床的野心。”An immunologist and chemical biologist, Dr. Kaufmann has experience in discovery and preclinical development of small molecule and biotherapeutics drug product candidates, including monoclonal antibodies, bispecific antibodies, antibody drug conjugates, cellular therapies, and vaccines. He brings expertise in multiple therapeutic areas, including immunology and oncology, as well as preclinical research strategies. He has, throughout his career, taken projects from inception through non-clinical R&D into clinical trials. In his most recent role as CSO at Oncternal Therapeutics, he led all preclinical research activities, oversaw the non-clinical development of a CAR T cell therapy as well as a small molecule prostate cancer program and supported translational research for the clinical programs. Previously, he held numerous roles of increasing responsibility at Sorrento Therapeutics, Inc., most recently serving as Senior Vice President of Immunotherapy, Head of Research and Global Partnerships. There, he built and led a discovery, research, and preclinical development team that successfully supported Sorrento's pipeline of therapeutic and immuno-oncology antibodies, bispecific antibodies, ADCs, oncolytic viruses, and cellular therapies. He also established an immuno-oncology research focus that resulted in a comprehensive portfolio, including out-licensed therapies. Dr. Kaufmann is an active member of the American Association for Cancer Research, the American Association of Immunologists, the Society for ImmunoTherapy of Cancer, and the American Society for Clinical Oncology. He has authored more than 50 peer-reviewed publications. He received his Ph.D. in Biology from The Scripps Research Institute, his Master of Science in Human Biology from the University of Greifswald, Germany, and his Bachelor of Science in Human Biology from The Philipps University, Germany. "I am honored to join Kyowa Kirin and work on innovative projects and partnerships that can contribute to addressing unmet medical needs," said Dr. Kaufmann. "I look forward to working with the incredible KKNA research team and our academic partners, including collaborators at the La Jolla Institute for Immunology, to bring new therapies to patients, their families and caregivers as well as the broader community that surrounds us all." About Kyowa Kirin Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a more than 70-year heritage, we apply cutting-edge science including expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America, and EMEA/International – we focus on our purpose to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about Kyowa Kirin North America at: https://kkna.kyowakirin.com or https://www.linkedin.com/company/kyowa-kirin-inc.-u.s./ SOURCE Kyowa Kirin